- GlobeNewswire•21 days agoProtalix BioTherapeutics Announces Additional Positive Data from its Phase I/II Clinical Trial for PRX-102 for the Treatment of Fabry Disease
CARMIEL, Israel, Aug. 10, 2016-- Protalix BioTherapeutics, Inc., announced today additional positive data from its phase I/II clinical trial of PRX-102 for the treatment of Fabry disease. PRX-102 is a ...
- Associated Press•23 days ago
The Carmiel, Israel-based company said it had a loss of 11 cents per share. The drug developer posted revenue of $1.8 million in the period. In the final minutes of trading on Monday, the company's shares ...
- GlobeNewswire•23 days ago
Patient Screening Underway for Fabry Phase III Clinical Trial. Data from the Cystic Fibrosis Phase II Clinical Trial Expected Around Year-End. CARMIEL, Israel, Aug. 08, 2016-- Protalix BioTherapeutics, ...
Protalix BioTherapeutics, Inc. (PLX)
NYSE MKT - NYSE MKT Delayed Price. Currency in USD
|Bid||0.59 x 5700|
|Ask||0.61 x 500|
|Day's Range||0.60 - 0.60|
|52wk Range||0.58 - 1.61|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||1.19|
|Avg Vol (3m)||121,510|
|Dividend & Yield||N/A (N/A)|